Palantir stock dropped 6.2% on June 3 after the UK Parliament intensified pressure to trigger a 2027 break clause in the company's NHS contract. In an ironic move, the market is pricing a political debate as a revenue event when the math says otherwise.
The disconnect: the narrative is about the NHS. The story is about $1.28 billion in U.S. commercial revenue growing 104% year-over-year in the first quarter of 2026.
Here's why the break clause noise doesn't move the thesis.
1. The NHS contract is a rounding error on this revenue base.
Palantir's NHS Federated Data Platform contract is worth £330 million over three years. That's roughly $415 million total, or about $138 million per year if amortized evenly. Palantir guided full-year 2026 revenue to $7.65–$7.66 billion. Even if the NHS contract vanished tomorrow - a scenario the contract terms don't support - it represents less than 2% of guided FY26 revenue. The bear case requires a magnitude of impact that doesn't exist.
2. The UK itself is 10% of the business, not the core.
In fiscal 2025, the United Kingdom accounted for $427 million out of $4.48 billion in total revenue - roughly 10%. That 10% already includes the NHS, Ministry of Defence (£240 million contract), police, and financial regulator deals. A worst-case full UK exit would trim about $450 million from FY26 guidance, bringing it to roughly $7.2 billion instead of $7.66 billion. That's material, but not existential. And the current news is about one contract, not the entire country.
3. U.S. commercial growth is the real engine - and it's accelerating.
Q1 2026 U.S. commercial revenue grew 104% year-over-year to $1.282 billion. For context, that single quarter of U.S. commercial revenue is nearly three times the entire UK's annual contribution. The growth is coming from enterprise AI platforms, not government data projects in Westminster. The break clause debate is happening in the wrong rearview mirror.
4. The valuation compressed on political theater, not fundamentals.
Palantir's P/E ratio fell from 260x in Q4 2025 to 153x in Q1 2026 and is now trading near 93x on forward FY26 estimates of $1.46 EPS. The stock has fallen from its 52-week high of $207.52 to around $136.50. The compression happened because political noise and analyst downgrades created a perfect storm of short-term panic. Q1 earnings beat on both revenue ($1.63 billion vs. $1.54 billion expected) and EPS ($0.33 vs. $0.28 expected). Guidance was raised, not cut. The fundamentals didn't change - the sentiment did.
5. The contract has built-in protections, not an easy exit.
The NHS contract includes review mechanisms and a 2027 break clause option - but NHS England can also choose not to extend beyond the initial three-year term. Hospital trusts are the ones using the platform, and the political pressure is coming from outside the operational chain. Breaking a contract this large in the middle of its term creates disruption costs that the government hasn't demonstrated it's willing to absorb.
The valuation anchor - and the problem.
Here's where the math gets honest. At $136.50, Palantir trades at approximately 93x forward FY26 EPS. That is not a GARP entry. The stock is still expensive by any traditional earnings-multiple framework. The opportunity here isn't that the valuation is attractive - it's that the bear narrative is wrong. If you believe 71% revenue growth sustains and FY27 EPS compounding is real, the stock can justify a premium multiple. If growth decelerates, 93x is punitive.
The NHS break clause is a headline, not a catalyst. It won't force a re-rate one way or the other because it doesn't move the earnings base. What matters is whether U.S. commercial growth holds and whether FY27 EPS estimates - which I wasn't able to pin down at a specific consensus number - begin converging at a level that compresses this forward multiple below the growth rate. Until then, the stock is priced for perfection, and political noise is just the latest reason the market pretends to have a thesis.
The break condition: A major UK-wide contract termination - not one NHS review - would force reassessment. But even then, the question is whether the market sells a 6% revenue hit at 93x earnings, or whether the rest of the growth machine absorbs the gap without touching the multiple.